- Allergan purchases Chase Pharmaceuticals
According to media reports, Allergan aquires US-based, clinical stage biopharma Chase Pharmaceuticals, thus enhancing its neurodegenerative disorders pipeline.
- MoH shall ensure that the maximum margins of the pharmaceutical market will not burden patients
The Ministry of Health (MoH) announced a series of measures to ensure better access of patients to medicines.
- Vtesse's Niemann-Pick C therapy granted PIM status
As per media reports, an investigational remedy in development for the treatment of Niemann-Pick Type C1 disease (NPC) has been awarded Promising Innovative Medicine (PIM) status by the Medicines and Healthcare products Regulatory Agency.
- Modern Hep C drugs grow in low-middle income countries
According to the World Health Organization (WHO), over one million people in low- and middle-income countries have been treated with new revolutionary, but controversial, hepatitis C drugs since their introduction two years ago.
- EMA: How to make better use of patient registries to collect high-quality data on medicines
As recently announced, workshop will be broadcast live tomorrow, October 28th, 2016 on the website of the European Medicines Agency (EMA).
- Medicines for Europe strongly supports the French government campaign to boost generic medicines
According to Medicines for Europe (formerly EGA), the generic medicines industry has over 60 manufacturing sites in France which produce around 55% of generic medicines used in the country today.
- NHS launches patient, staff-led Twitter account
As per a new press release posted on its website, the National Health Service (NHS) partners with Twitter to help shed light on what it means to work or be a patient in the NHS.
- EFPIA statement on the ENVI Committee's draft report on EU options for improving access to medicines
The European Federation of Pharmaceutical Industries and Associations (EFPIA) notes the publication of the European Parliament’s ENVI Committee draft report on EU options for improving access to medicines.
- Bristol-Myers Squibb and Nektar to test immunotherapy combinations in cancer
According to media reports, Bristol-Myers Squibb has signed a clinical trials agreement with Nektar Therapeutics that will test a combination of the firms' immunotherapy drugs across a range of cancer indications.
- EMA: IT systems unavailable from October, 28th to November, 1st 2016
As reported in a new announcement posted by the European Medicines Agency (EMA), its website and online applications will be temporarily unavailable.
In an unexpected move, just before the end of 2011, ...
Improving expenditure efficiency has been, for a ver...
Your Portal Link to Mass Media Universe.
Valuable Quarterly Romanian Market Analysis.
Ask the analyst
Tailor-made advice for you